
Corcept Therapeutics (CORT) Stock Forecast & Price Target
Corcept Therapeutics (CORT) Analyst Ratings
Bulls say
Corcept Therapeutics is expected to see continued success with its flagship product, Korlym, which is seeing strong demand and now has an authorized generic version available. Additionally, the company has a diverse pipeline of promising treatments in various stages of clinical trials, which provide potential for future growth. The recent approval and launch of Lifyorli in platinum-resistant ovarian cancer are also positive indicators for the company's financial outlook. While risks such as commercial, clinical, and regulatory challenges remain, the company's recent financial performance and positive developments suggest a strong potential for continued success and growth in the future.
Bears say
Corcept Therapeutics is facing a negative outlook due to their reliance on one main drug, Korlym, for revenue and their limited pipeline. With limited data on their other compounds, the market may not have confidence in their potential to diversify and continue revenue growth. Furthermore, the company's financials show a decrease in revenue and net income in the 2020 fiscal year compared to the previous year, further exacerbating concerns about their future success.
This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Corcept Therapeutics (CORT) Analyst Forecast & Price Prediction
Start investing in Corcept Therapeutics (CORT)
Order type
Buy in
Order amount
Est. shares
0 shares